{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T05:24:52Z","timestamp":1695705892988},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>PSMA PET\/CT is known to show uptake in various benign and malignant processes. The following PSMA PET\/CT was performed for prostate carcinoma staging (Gleason 3 + 4 left apex; PSA 5.8). It shows incidental diffuse PSMA marrow uptake, not typical for prostate metastatic disease. No treatment had been commenced at the time of the scan. Serology and bone marrow biopsy showed B-cell acute lymphocytic leukemia. Focal PSMA uptake in the right ischium was correlated with a T1 hypointense lesion on a previous MRI and was convincing for a skeletal metastasis. Alternative diagnoses in diffuse skeletal PSMA uptake need therefore to be considered.<\/jats:p>","DOI":"10.1097\/rlu.0000000000002712","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T12:13:13Z","timestamp":1563192793000},"page":"e529-e531","source":"Crossref","is-referenced-by-count":1,"title":["Incidental Finding of Acute Lymphocytic Leukemia in a Prostate-Specific Membrane Antigen PET\/CT"],"prefix":"10.1097","volume":"44","author":[{"given":"Christian","family":"Acksteiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Sounness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1021\/jm100623e","article-title":"68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer","volume":"53","year":"2010","journal-title":"J Med Chem"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib3-20230925","first-page":"462","article-title":"The role of 68Ga-PSMA PET\/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature","volume":"70","year":"2018","journal-title":"Minerva Urol Nefrol"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","article-title":"68Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bju.13397","article-title":"68Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment","volume":"117","year":"2016","journal-title":"BJU Int"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3348\/kjr.2018.19.5.819","article-title":"Prostate-specific membrane antigen PET imaging in prostate cancer: opportunities and challenges","volume":"19","year":"2018","journal-title":"Korean J Radiol"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls","volume":"38","year":"2018","journal-title":"Radiographics"},{"key":"bib8-20230925","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","year":"1997","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T05:13:53Z","timestamp":1695618833000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002712","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,15]]}}}